- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02551627
A Study to Investigate the Impact of a Multiple Micronutrient (MMN) Beverage Powder on Vaccine Response in School Children
December 19, 2017 updated by: GlaxoSmithKline
Impact of a Multiple Micronutrient (MMN) Beverage Powder on Vaccine Response in School Children (7-10yrs; Inclusive) in Bangladesh: a Randomised, Double Blind Controlled Trial
This will be a double blind, two-arm, parallel-group, stratified for gender, randomised, controlled study in participants aged 7-10 years (yrs).
The aim of the study is to test the hypothesis that MMN fortified beverage may help improve immunity outcomes as assessed through vaccine response in 7-10 yrs old school participants.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
7 years to 10 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Understanding and willingness to participate in the study as demonstrated by participants' parents and/or Legally acceptable representatives (LARs) voluntary written informed consent, participants' written assent
- Participants aged between 7-10 yrs, inclusive
- Good general and mental health
- Participants with Z-scores of BMI for age of ≥-3 to ≤+1
Exclusion Criteria:
- Children in Care (CiC)
- Known or suspected intolerance or hypersensitivity to the study material or any of their stated ingredients or any known food allergies like peanut allergy, gluten allergy or lactose intolerance
- Participant who has already been administered cholera vaccine in any form prior to this study and any known contra-indication to oral cholera vaccine
- Participant who consumed any antibiotics during the week prior to the first dose of study vaccination until the end of the study
- Severe anemia (Hb < 8 g/dL), recent history (2 months) of serious infections, injuries and/or surgeries
- Participant consuming nutritional supplement and/or health food drinks on regular basis (≥ 3 times a week) in last 3 months
- Current or relevant history of any serious, severe or unstable physical or psychiatric illness or any medical disorder
- Participants likely to move out of geographical range of the study within study duration
- Child of an employee of the sponsor or the study site or members of their immediate family, sibling of participant already enrolled in the study
- Previous participation in this study, in another clinical study or receipt of an investigational drug within 30 days of screening visit; participation in any nutritional study or didactic nutritional education in last 6 months of the screening visit
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Test Product
MMN fortified beverage powder [27 gram (g)] made up in 150 milliliter (mL) of water, will be administered orally as a single serve, twice daily for 18 weeks.
|
MMN fortified beverage powder.
|
|
Active Comparator: Control
Isocaloric beverage powder without micronutrient fortification (27 g), made up in 150 mL of water will be administered orally as a single serve, twice daily for 18 weeks.
|
Isocaloric beverage powder without micronutrient fortification.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vaccine response test
Time Frame: 18 weeks
|
Proportion of participants demonstrating vaccine reponse, receiving either test product or control will be determined and compared.
Vaccine response will be defined as greater than or equal to 4 fold increase from pre-vaccine visit in vibriocidal antibody response 7 days post second vaccine dose.
|
18 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Absolute vibriocidal antibody titer
Time Frame: 18 weeks
|
Blood will be drawn by qualified study personnel as per visits and antibody levels will be assessed.
|
18 weeks
|
|
Change from baseline in nutrional biochemistry
Time Frame: 18 weeks
|
Change in nutritional biochemistry for micronutrients vitamins A, B6, B12, C, D, E, folate and of the trace elements (selenium, zinc, copper, iron), ferritin, serum transferrin receptor (sTfR), C-reactive protein (CRP), alpha 1-acid glycoprotein (AGP) from baseline to end of the intervention will be measured from the drawn blood.
|
18 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2016
Primary Completion (Anticipated)
October 1, 2017
Study Completion (Anticipated)
October 1, 2017
Study Registration Dates
First Submitted
September 14, 2015
First Submitted That Met QC Criteria
September 14, 2015
First Posted (Estimate)
September 16, 2015
Study Record Updates
Last Update Posted (Actual)
December 20, 2017
Last Update Submitted That Met QC Criteria
December 19, 2017
Last Verified
December 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- 204476
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Growth and Development
-
The University of Texas Health Science Center,...CompletedGrowth & DevelopmentUnited States
-
GlaxoSmithKlineHammersmith Medicines ResearchCompletedGrowth and DevelopmentUnited Kingdom
-
DSM Nutritional Products, Inc.Charite University, Berlin, Germany; Ludwig-Maximilians - University of Munich and other collaboratorsCompletedGrowth and DevelopmentSerbia
-
GlaxoSmithKlineMahajan Imaging CenterCompleted
-
GlaxoSmithKlineCompletedGrowth and DevelopmentIndia
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedGrowth and DevelopmentIndia
-
Annamalai UniversityJohns Hopkins Bloomberg School of Public Health; Global Alliance for Improved... and other collaboratorsUnknownChild Development | Morbidity | Cognitive Development | Physical GrowthBangladesh
-
Société des Produits Nestlé (SPN)Veeva Systems; SAS InstituteRecruitingBrain | Growth & DevelopmentChina
-
Mead Johnson NutritionCompletedGrowth | Cognitive DevelopmentUnited States
Clinical Trials on Test Product
-
Boehringer IngelheimCompleted
-
Danone ResearchCompleted
-
GlaxoSmithKlineCompletedDenture RetentionUnited States
-
IBSA Farmaceutici Italia SrlInformapro SrlRecruitingSupplementation | Hypercholesterolemia and HyperlipidemiaItaly
-
Coloplast A/SCompletedCompliance, PatientDenmark
-
Coloplast A/SCompletedStoma Site LeakageDenmark
-
Medicis Global Service CorporationCompletedSeborrheic DermatitisUnited States
-
Pierre Fabre Dermo CosmetiqueRecruiting
-
Nutricia ResearchCompletedGrowth | Tolerance | Safety | Subjects in Need of a Human Milk Fortifier (HMF)Netherlands, France, Germany, United Kingdom